GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Aurobindo Pharma Ltd

Aurobindo Pharma: Russian Subsidiary Auro Pharma LLC Ownership Transfer Approved

M&A ● No Immediate Change LOW RISK
📅 Filed on BSE: 04 Nov 2026, 08:34 PM IST  ·  BSE ID: d6e9a360-de59-43d6-a259-5037186776f4
View Original BSE Filing (PDF)
💡
In Simple Terms
Aurobindo Pharma is moving its Russian subsidiary, Auro Pharma LLC, between its own group companies for about INR 29 crore as an internal shuffle.
🤖 AI Summary
  • Aurobindo Pharma's board approved transfer of Auro Pharma LLC, Russia ownership for ~INR 29 cr.
  • Auro Pharma LLC, a step-down subsidiary, shifts from Auroactive Pharma to Auropharm Overseas.
  • The transaction involves 100% stake and is an internal group reorganization exercise.
  • Auro Pharma LLC reported Nil turnover for FY2026, FY2025, and FY2024.
  • No governmental or regulatory approvals are required; completion expected in 60-90 days.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Turnover of Auro Pharma LLC for FY 2026
Nil INR million
Turnover of Auroactive Pharma Pvt. Ltd. for FY 2026
701.3 INR million
Turnover of Auropharm Overseas Ltd. for FY 2026
Nil INR million
Consideration for Auro Pharma LLC transfer
~INR 29 cr.
🏢 How This Affects the Company
📈
Business Impact
This internal transfer is a restructuring of existing assets and does not introduce new business lines or change the overall market presence for Aurobindo Pharma.
💰
Financial Impact
The transaction involves a cash consideration of ~INR 29 cr. for the transfer of a subsidiary with Nil turnover in FY2026, FY2025, and FY2024, representing an internal cash movement within the group.
⚙️
Operational Impact
The transfer is intended to streamline the holdings of the Russian subsidiary within the group, potentially improving internal administrative efficiency without altering external operations.
⚠️
Risk Impact
The transaction is between wholly-owned subsidiaries and is undertaken at arm’s length, indicating no new external counterparty risks or financial exposure.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders as this is an internal group restructuring transaction.
👤
Who Is Affected
All shareholders of Aurobindo Pharma Ltd are indirectly affected by the internal reorganisation of its step-down subsidiaries, Auro Pharma LLC, Auroactive Pharma Private Limited, and Auropharm Overseas Limited.
🔍
Management Signal
This decision signals management's intent to optimize and streamline internal group structures and asset holdings for operational efficiency.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Completion of transfer formalities for Auro Pharma LLC within the 60-90 day timeline.
Future disclosures regarding any subsequent internal restructuring within the group.
Q3 FY27 financial results for broader company performance update.
LOW RISK The transaction is an internal reorganization between wholly-owned subsidiaries, reducing external risks.
💡 Investor Takeaway
Aurobindo Pharma's board approved an internal transfer of Auro Pharma LLC, Russia, for ~INR 29 cr., from Auroactive Pharma to Auropharm Overseas. This aims to streamline group holdings; Auro Pharma LLC recorded Nil turnover in FY2026, FY2025, and FY2024.
⚖️ Strengths & Concerns

✅ Positives

  • The transaction is an internal reorganization, indicating management's focus on streamlining group structure for efficiency.
  • No governmental or regulatory approvals are required, suggesting a smooth process and potentially faster completion within 60-90 days.

⚠️ Concerns

  • Auro Pharma LLC, the entity being transferred, reported Nil turnover for FY2026, FY2025, and FY2024.
  • The cash consideration of ~INR 29 cr. for an entity with Nil turnover for three consecutive fiscal years represents an internal capital allocation.
📅 Company Track Record
This internal reorganization follows Aurobindo Pharma's recent strategic moves, including the approved merger of two API subsidiaries, Apitoria Pharma (INR 64,430.8 million turnover) with Auroactive Pharma, and the consolidation of three injectable pharma subsidiaries in August 2026. Earlier, a subsidiary acquired 80% of A1 Biochem Group for USD 17 million in July 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the key event announced by Aurobindo Pharma regarding Auro Pharma LLC?
Aurobindo Pharma's board approved the transfer of ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited.
What is the consideration for the transfer of Auro Pharma LLC?
The consideration for the transfer of Auro Pharma LLC is approximately ~INR 29 cr., subject to adjustments, as on the date of transfer.
What was the turnover of Auro Pharma LLC for the last three fiscal years?
Auro Pharma LLC reported Nil turnover for the financial years ended March 31st, 2026, 2025, and 2024.
What is the purpose of this ownership transfer for Aurobindo Pharma?
The proposed share transfer is part of an internal reorganization exercise to streamline the holdings of the Russian subsidiary within the group companies.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.